CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (101,354)	$ (45,370)	$ (25,860)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	14,679	9,653	7,088
Amortization of debt issuance costs	49	49	49
Stock-based compensation	19,873	11,245	6,784
Inventory write-down	14,437	0	0
Deferred taxes	(898)	252	(39)
Impairment expense	3,279	0	0
Change in fair value of preferred stock warrant liability	0	10,624	(749)
Changes in assets and liabilities:
Accounts receivable	1,605	(9,110)	(740)
Inventory	(24,742)	(48,476)	(13,867)
Prepaid expenses and other current assets	18,100	(11,505)	(11,249)
Operating lease right-of-use assets and current and noncurrent lease liabilities	12,265	0	0
Accounts payable and accrued expenses	(37,593)	25,240	1,249
Other long-term liabilities	(10,157)	5,289	1,944
Deferred revenue	(126)	1,259	812
Net cash used in operating activities	(90,583)	(50,850)	(34,578)
Cash flows from investing activities:
Purchase of property and equipment	(31,363)	(24,181)	(14,350)
Investment in equity securities	0	(250)	(2,000)
Changes in security deposits	(929)	(1,205)	69
Net cash used in investing activities	(32,292)	(25,636)	(16,281)
Cash flows from financing activities:
Proceeds from initial public offering, net of underwriting discounts and commissions	0	236,964	0
Proceeds from the issuance of preferred stock, net of issuance costs	0	0	101,749
Proceeds from bank loans	0	0	18,294
Principal payments on bank loans	0	0	(18,294)
Payments of deferred offering costs	(744)	(4,691)	0
Repayment of non-recourse promissory note	539	0	0
Proceeds from issuance of common stock under the employee stock purchase plan	1,201	0	0
Proceeds from the exercise of common stock warrants	0	395	0
Proceeds from the exercise of stock options	2,751	5,484	440
Taxes withheld and paid on employee stock awards	(166)	0	0
Net cash provided by financing activities	3,581	238,152	102,189
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash	(1,515)	(341)	909
Net (decrease) increase in cash, cash equivalents, and restricted cash	(120,809)	161,325	52,239
Cash, cash equivalents, and restricted cash—beginning of year	288,576	127,251	75,012
Cash, cash equivalents, and restricted cash—end of year	167,767	288,576	127,251
Supplemental disclosures of cash flow information:
Cash paid for interest	88	118	235
Cash paid for taxes	1,424	438	110
Noncash investing and financing activities:
Purchase of property and equipment included in accrued liabilities	601	979	138
Repurchase of stock options	0	0	640
Non-cash exercise of common stock warrants	35	39	0
Deferred offering costs included in accrued liabilities	0	744	0
Stock-based compensation included in capitalized internal-use software	1,199	0	0
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents	167,136	288,576	126,551
Restricted cash included in prepaid expenses and other current assets	632	0	700
Total cash, cash equivalents, and restricted cash	$ 167,767	$ 288,576	$ 127,251